Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

CONCLUSIONS: The graded salutary relationship between efpeglenatide dose and cardiovascular outcomes suggests that titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to high doses may maximize their cardiovascular and renal benefits.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03496298.PMID:36802715 | DOI:10.1161/CIRCULATIONAHA.122.063716

Source: Circulation - February 21, 2023 Category: Cardiology Authors: Hertzel C Gerstein Zhuoru Li Chinthanie Ramasundarahettige Seungjae Baek Kelley R H Branch Stefano Del Prato Carolyn S P Lam Renato D Lopes Richard Pratley Julio Rosenstock Naveed Sattar Source Type: research